Quantum-Si Incorporated (Nasdaq: QSI):
WHAT: The protein sequencing company, Quantum-Si, will discuss their novel next-generation protein sequencing platform, PlatinumTM and how it can complement immunoassays and other proteomic workflows by providing deeper insights into proteins. The session will also be joined by Professor of Chemical and Biological Engineering at the Northwestern University, Dr. Danielle Tullman-Ercek. Dr. Tullman-Ercek will illustrate how protein identification on Platinum was utilized in her research to provide additional information about proteins typically studied via conventional western blot and mass spectrometry techniques. She will demonstrate how next-generation protein sequencing provides additional information about proteins, comparing results from conventional techniques to those obtained from next-generation protein sequencing.
WHY: About nine out of 10 drugs target proteins in some capacity, but currently over 85% of the proteome is undrugged. Technologies like Quantum-Si’s Platinum will open this bottleneck on researching the proteome and developing new therapeutics. Quantum-Si’s benchtop device is the only technology available currently that allows for single-molecule protein sequencing.
WHO: Quantum-Si and Northwestern University will bring together researchers with expertise in fields including molecular biology, biochemistry, and genetics who have interest in expanding into proteomics. The webinar will be moderated by:
- Katherine Johnson, Senior Director, Product, Quantum-Si
- Dr. Danielle Tullman-Ercek, Professor of Chemical and Biological Engineering, Northwestern University
WHEN: “Next-generation protein sequencing platform: Advances in protein identification & characterization” will be heldFriday, October 6, 2023, at 11:00 a.m. ET / 8:00 a.m. PT.
WHERE: Wherever you are – home office, study, etc. Reserve your spot today here:https://www.selectscience.net/register.aspx?itemID=2089&itemTypeID=54
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231005920138/en/
